Table 1 Clinical characteristics
At SU target (<0.36 mmol/L) | Above SU target (≥0.36 mmol/L) | p | |
|---|---|---|---|
n = 89 | n = 184 | ||
Age, years, mean (SD) | 61 (14) | 58 (16) | 0.09 |
Male sex, n (%) | 52 (58%) | 143 (77.7%) | 0.002 |
Māori or Pacific ethnicity, n (%) | 15 (17%) | 49 (26.6%) | 0.09 |
Disease duration, years, mean (SD) | 5.6 (4.8) | 5.0 (3.0) | 0.22 |
Treatment in secondary care, n (%) | 16 (18%) | 52 (28.2%) | 0.07 |
Body mass index, kg/m2, mean (SD) | 30.4 (6.8) | 31.6 (6.5) | 0.16 |
Diuretic use, n (%) | 26 (29%) | 54 (29.3%) | 1.0 |
Any ULT, n (%) | 74 (83%) | 107 (58.1%) | <0.001 |
Allopurinol use, n (%) | 74 (83%) | 103 (56.0%) | <0.001 |
Allopurinol dose for patients on allopurinol, mg/day, mean (SD) | 235 (87) | 194 (98) | 0.004 |
Probenecid use, n (%) | 2 (2%) | 6 (3.2%) | 1.0 |
Colchicine use, n (%) | 26 (31%) | 61 (33.2%) | 0.58 |
Non-steroidal anti-inflammatory use, n (%) | 14 (16%) | 43 (23.4%) | 0.16 |
Serum urate, mmol/L, mean (SD) | 0.27 (0.07) | 0.47 (0.09) | <0.001 |
Serum creatinine, μmol/l, mean (SD) | 99 (77) | 110 (62) | 0.23 |
Creatinine clearance, ml/min, mean (SD) | 68 (27) | 70 (30) | 0.51 |